{"disease":{"id":"cerebral-stroke","name":"cerebral stroke"},"drugs":{"marketed":[{"drug_id":"technetium-tc-99m-exametazime","indication_name":"Detection of altered cerebral perfusion in stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceretec","generic_name":"TECHNETIUM TC 99M EXAMETAZIME","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"}],"pipeline":[],"offLabel":[],"totalMarketed":34,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07052656","title":"Risk Factors and Outcomes in Patients Treated in Neurocritical Care","phase":"","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06077305","title":"A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05169021","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT03209258","title":"The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":7067,"lead_sponsor_name":"The George Institute for Global Health, China","has_results":false},{"nct_id":"NCT05378490","title":"The Akershus Study of Ischemic Stroke and Thrombolysis -1","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT03281590","title":"Stroke and Cerebrovascular Diseases Registry","phase":"","overall_status":"COMPLETED","enrollment_count":4594,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT03685578","title":"CERENOVUS Neurothrombectomy Devices Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Cerenovus, Part of DePuy Synthes Products, Inc.","has_results":false},{"nct_id":"NCT05502874","title":"Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06587737","title":"Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1125,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT05614193","title":"Deep Enhanced Imaging in Stroke and Vascular Neurology","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT06402968","title":"Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Zeenat Qureshi Stroke Institute","has_results":false},{"nct_id":"NCT03085472","title":"Chongqing Intracerebral Hemorrhage Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04447599","title":"Conjunctival and Retinal Vascularization and Small Vessel Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":850,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06530537","title":"Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":848,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT07449910","title":"Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"The First Affiliated Hospital of University of Science and Technology of China","has_results":false},{"nct_id":"NCT03243539","title":"Implementation of Neuro Lung Protective Ventilation","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":728,"lead_sponsor_name":"Colin Grissom","has_results":false},{"nct_id":"NCT05300997","title":"Translational Immunodiagnostics in Stroke (TrImS)","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06674460","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06614972","title":"Balloon-expandable DES for ICAS Registry Study (BDES-ICAS Registry)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":520,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06735274","title":"Transcranial Doppler (TCD) Ultrasound and Cognition in Cerebral Vascular Disease. (SUNRISE)","phase":"","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Universidade do Porto","has_results":false},{"nct_id":"NCT06954610","title":"Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT05473637","title":"Taiwan Associated Genetic and Nongenetic Small Vessel Disease","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03325946","title":"The FBRI VTC Neuromotor Research Clinic","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Virginia Polytechnic Institute and State University","has_results":false},{"nct_id":"NCT03815149","title":"Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Gold Coast Hospital and Health Service","has_results":false},{"nct_id":"NCT03177161","title":"Assessment of Patient Reported Health Status Questions Via Four Different Methods of Administration, in Stroke Survivors.","phase":"NA","overall_status":"COMPLETED","enrollment_count":472,"lead_sponsor_name":"Dr Jonathan Hewitt","has_results":false},{"nct_id":"NCT06260969","title":"Endovascular Treatment of Acute Ischemic Stroke With Underlying Intracranial Artery Stenosis","phase":"","overall_status":"UNKNOWN","enrollment_count":470,"lead_sponsor_name":"Tianjin Huanhu Hospital","has_results":false},{"nct_id":"NCT04657133","title":"Remote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":452,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT03451591","title":"LACunar Intervention (LACI-2) Trial-2","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"University of Edinburgh","has_results":true},{"nct_id":"NCT05611918","title":"REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":350,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT01758614","title":"The Carotid and Middle Cerebral Artery Occlusion Surgery Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT04712591","title":"The EBC Recovery Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04554368","title":"A Novel Score to Predict Risk of Symptomatic Intracerebral Hemorrhage","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","has_results":false},{"nct_id":"NCT03148340","title":"Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology","phase":"","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Cerebrotech Medical Systems, Inc.","has_results":false},{"nct_id":"NCT02881957","title":"Hypovitaminosis D in Neurocritical Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT02270736","title":"Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Merz Pharmaceuticals GmbH","has_results":true},{"nct_id":"NCT03094715","title":"Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window","phase":"NA","overall_status":"TERMINATED","enrollment_count":253,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT03417349","title":"Safety and Effectiveness of SOFIA™/SOFIA™ PLUS for Direct Aspiration in Acute Ischemic Stroke","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Dr. Markus Alfred Möhlenbruch","has_results":false},{"nct_id":"NCT04808778","title":"Stroke Prevention in Young Adults With Sickle Cell Anemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT01603602","title":"BOTOX® Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01603615","title":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT07422636","title":"Wet and Dry Biomarkers to Predict Secondary Injury in Stroke: From Bench to Bedside - The NIMBLE Study","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT04330222","title":"Cambridge 7 Tesla Cerebral Small Vessel Disease Study","phase":"","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"University of Cambridge","has_results":false},{"nct_id":"NCT05725694","title":"Acute Ischaemic STROKE: From LAboratory to the Patient's BED","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Istituto di Neuroscienze Consiglio Nazionale delle Ricerche","has_results":false},{"nct_id":"NCT05901259","title":"The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Exoneural Network AB","has_results":false},{"nct_id":"NCT04971564","title":"Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT05746221","title":"INflammation and Small Vessel Disease Study","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Cambridge","has_results":false},{"nct_id":"NCT04858841","title":"Post-stroke Epilepsy: Primary Prophylaxis Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"National Cheng Kung University","has_results":false},{"nct_id":"NCT05419193","title":"PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}